-
Amazing! The 8-week cure rate of abbvie hepatitis C new compound is as high as 99%
Time of Update: 2017-01-11
Source: on January 9, 2017, abbvie announced the first-line results of the phase III certain-1 study of glecaprevir / pibrentasvir (g / P, abt-493 / abt-530, NS3A / NS5A) 300mg / 120mg in Japanese pat
-
No longer unattainable, abbvie's new drug may shake Gilead's sovaldi supremacy
Time of Update: 2014-11-24
Source: Biovalley 2014-11-24 if you want to ask which is the best in drug research and development of biomedical industry in the past two years? It is believed that 99% of analysts will mention the co
-
The European Medicines Agency gives the green light to abbvie's hepatitis C combination
Time of Update: 2014-11-24
ABB vie's hepatitis C treatment combination drug is expected to be approved by the European drug administration, while waiting for the FDA review results, only a step away from successfully challengin
-
Shire, a drug producer in London, plans to accept abbvie's offer
Time of Update: 2014-07-15
Source: Tencent finance, a London listed drug manufacturer on July 15, 2014, has given in to its 31 billion pound ($53 billion) takeover offer after raising its offer to abbvie, a US peer company, on
-
Ireland shire PLC confirms the fourth contact with abbvie
Time of Update: 2014-07-14
Source: great wisdom astak news agency on July 14, 2014, Irish pharmaceutical company shire PLC released a notice on Friday confirming that the company is in contact with American pharmaceutical compa
-
Express New strategies for targeting "drug-free" targets! AbbVie reached a $540 million partnership
Time of Update: 2023-02-01
▲Anima Biotech's technology platform can screen specific small molecule compounds for a variety of proteins that regulate mRNA translation (Image source: Anima Biotech official website)Under the agreement, Anima will receive an upfront payment of $42 million and is eligible for up to $540 million based on AbbVie's selection and R&D and commercialization milestones across the three targets.
-
$255 million! AbbVie acquires DJS Abodies
Time of Update: 2022-10-25
£6 million in funding announced in 2020 Dr. Jonathon Sedgwick, vice president and head of global discovery research at AbbVie, said, "We are delighted to bring the innovative science behind DJS-002 and the talented team of DJS to AbbVie. The acquisition will provide new capabilities to strengthen our current antibody research activities, provide opportunities to strengthen our immunology portfolio and provide a solid foothold for expanded research efforts at the Dynamic Biosciences Centre in Oxford, UK.
-
pharmaceutical companies in the century, AbbVie, Pfizer, Lilly...
Time of Update: 2022-10-14
Note: The list only counts pharmaceutical companies with revenues of more than $10 billion in 2021; Revenue per capita is revenue for 2021 divided by the total number of employees in the company Data source: References With mRNA COVID-19 vaccine With mRNA COVID-19 vaccine BioNTech/Moderna topped the list BioNTech/Moderna topped the list Three years ago, with the COVID-19 pandemic and the success of the mRNA COVID-19 vaccine, BioNTech and Moderna topped the list of the world's most efficient pharmaceutical companies.
-
AbbVie's JAK inhibitor "Upatinib Sustained-Release Tablets" is expected to be approved in China in the near future
Time of Update: 2022-05-29
It is hoped that AbbVie Upatinib Sustained-Release Tablets will be approved in China as soon as possible, which will provide new treatment options for Chinese patients with atopic dermatitis!References:[1] Drug registration progress query on NMPA official website.
-
AbbVie Upatinib Approved in my country to Inventory 8 Iteratively Marketed JAK Inhibitors Worldwide
Time of Update: 2022-05-28
0202Approved JAK inhibitors in my country and their research statusApproved JAK inhibitors in my country and their research statusWith the approval of AbbVie Upatinib, 4 JAK inhibitors have been approved in China, and the remaining 3 are: Novartis' ruxolitinib, Eli Lilly's baricitinib, and Pfizer's tofacitinib Cloth, the indications mainly cover rheumatoid arthritis, myelofibrosis, atopic dermatitis .
-
The symptoms of nearly half of the express patients improved by at least 40%, and AbbVie's JAK inhibitor was approved by the FDA
Time of Update: 2022-05-28
S. FDA approved the expanded indication of its JAK inhibitor Rinvoq (upadacitinib, upadacitinib) for the treatment of active ankylosing spondylitis (ankylosing spondylitis, AS) adult patients .
Reference: [1] RINVOQ® (upadacitinib) Approved by US FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis.
-
AbbVie's JAK Inhibitor "Upatinib" Approved in China for the Third Indication
Time of Update: 2022-05-25
Article source: Medical Cube InfoOn April 6, the official website of the Food and Drug Administration showed that another marketing application for AbbVie’s upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs.
-
50+ anti-PD drugs have been approved for marketing; multi-enterprise joint deployment, Nuggets innovative therapies, AbbVie, Biogen...
Time of Update: 2022-05-22
Published results of a Phase 1b clinical trial of the drug in PD showed that of 15 patients with advanced PD who received a single gene therapy treatment, 14 patients still experienced improvement in disease grade after 3 years of treatment .
-
AbbVie Announces Phase 2 Clinical Data of navitoclax in Myelofibrosis 2022 AACR
Time of Update: 2022-05-21
Recently, AbbVie presented new data from the Phase 2 REFINE (NCT03222609) trial of navitoclax in combination with ruxolitinib (a JAK1/2 inhibitor) in myelofibrosis (MF) at the 2022 American Association for Cancer Research (AACR) annual meeting .
-
FDA approves AbbVie's JAK inhibitor Rinvoq for atopic dermatitis
Time of Update: 2022-02-23
S. Food and Drug Administration announced today that it has approved an expanded indication for AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in adults or children 12 years and older who have not responded to prior therapy and are The condition cannot be controlled by other treatments, or other treatments should not be used .